Key result
Serelaxin has demonstrated promise in early clinical trials as a safe and well-tolerated therapy for acute heart failure, with definitive outcomes data currently being assessed.
Why the study?
Does serelaxin improve outcomes in patients with acute heart failure?
Does serelaxin improve outcomes in patients with acute heart failure?
Serelaxin is a promising novel therapy for acute heart failure that is currently awaiting definitive outcomes data from a large multi-center trial.
Serelaxin should not change acute heart failure practice; leaves open its role pending definitive large-trial outcomes.
Outcomes for patients with acute heart failure remain suboptimal and treatments principally target improvement of symptoms. To date there has been no therapy approved for acute heart failure shown to improve mortality or readmission risk post-discharge. Serelaxin, a recombinant form of the naturally occurring polypeptide hormone relaxin, has demonstrated promise in preclinical and early clinical trials as a potentially novel therapy for acute heart failure. It is postulated through its anti-fibrotic and vasodilatory effects that this agent can improve outcomes in both the short and long term in these patients. Randomized clinical data has suggested that the medication is safe and well tolerated. However, definitive outcomes data is currently being assessed in a large multi-center trial.
No takes yet. Share an insight, caveat, or question.
Moin et al. (2016) conducted a review in Acute heart failure. Serelaxin was evaluated. Serelaxin has demonstrated promise in early clinical trials as a safe and well-tolerated therapy for acute heart failure, with definitive outcomes data currently being assessed.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: